In our study, we found there were higher levels of C3 and C4 in SARS-CoV-2 sepsis patients, thus we believe that the treatment of inhibiting hyperactivation of the complement system in SARS-CoV-2 sepsis may be worthy of further study. This evidence concerns the gene C4A and Sepsis.